Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Quantitative Mass Spectrometry for Characterizing Post-Translational Modifications of Recombinant Therapeutic Proteins

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Quantitative Mass Spectrometry for Characterizing Post-Translational Modifications of Recombinant Therapeutic Proteins

Quantitative Mass Spectrometry for Post-Translational Modification Analysis

CELL & GENE | RNA | BIOLOGICS

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

  • Precision Proteomics for Therapeutic Integrity*
Technical Question Franklin Biolabs Response
What is the typical limit of detection for PTM site occupancy? For targeted LC-MS/MS methods like Parallel Reaction Monitoring (PRM), we can achieve low single-digit percentage occupancy quantification. This level of sensitivity is necessary for identifying and monitoring low-abundance modifications that function as quality attributes (CQAs).
How does LC-MS/MS differentiate between isobaric modifications? High-resolution mass spectrometry (HRMS) instruments, such as Orbitrap platforms, provide the mass accuracy to distinguish subtle mass differences. Fragmentation patterns in MS/MS spectra are also unique to specific modifications and their locations, allowing for unambiguous identification of isobaric species like phosphorylation and sulfation.
Which sample preparation methods are best for preserving labile PTMs? To preserve labile modifications like phosphorylation, we employ protocols that include phosphatase and protease inhibitors throughout the entire sample preparation workflow. Techniques such as Titanium Dioxide (TiO2) or Immobilized Metal Affinity Chromatography (IMAC) enrichment are used to isolate phosphopeptides prior to LC-MS/MS analysis.
Can you quantify PTMs in complex biological matrices? Yes. We develop and validate GxP-compliant methods for quantifying PTMs directly from matrices such as plasma or tissue homogenates. This involves stable isotope-labeled internal standards and targeted acquisition strategies to ensure accuracy and reproducibility, supporting pharmacokinetic and pharmacodynamic assessments.

Post-translational modifications (PTMs) are definitive quality attributes (CQAs) for recombinant therapeutic proteins, directly influencing their efficacy, stability, and immunogenicity. Quantitative mass spectrometry provides the required specificity and sensitivity to characterize these modifications with high precision. This analysis is fundamental for establishing lot-to-lot consistency, supporting Chemistry, Manufacturing, and Controls (CMC) documentation, and de-risking the path to regulatory submission.

The Requirement for Deep Proteomic Characterization

The biological activity of a therapeutic protein is dictated by its three-dimensional structure, which is heavily influenced by PTMs such as glycosylation, phosphorylation, and oxidation. Inconsistent or incorrect modifications can lead to a loss of function or an unintended immune response. A comprehensive PTM profile is a required component of any successful biologics development program.

This need for deep molecular characterization of the therapeutic agent mirrors the analytical rigor applied to the delivery vehicle. For instance, understanding the systemic delivery and sustained expression of therapeutic proteins from viral vectors is a key translational insight (PMID: 12189244). Similarly, characterizing vector integration patterns provides vital safety data for gene therapies (PMID: 37930949). The same level of scrutiny must be applied to the protein payload itself to ensure its molecular integrity and intended biological effect.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Methodologies for Quantitative PTM Analysis

Our GxP-compliant laboratories utilize a suite of mass spectrometry techniques to build a complete PTM profile for your therapeutic protein.

  • Peptide Mapping: After enzymatic digestion, LC-MS/MS is used to identify the specific amino acid residues where modifications occur.

  • Intact Mass Analysis: High-resolution mass spectrometry determines the mass of the intact protein, revealing the overall PTM profile and distribution of major glycoforms.

  • Tandem Mass Spectrometry (MS/MS): Fragmentation analysis provides definitive structural information, enabling precise localization of PTMs and differentiation of isomers.

These methods are applied in a phase-appropriate manner, from early discovery and clone selection to formal characterization for regulatory filings.

From Analytical Data to IND Submission

Robust PTM characterization data forms a cornerstone of the CMC package for an Investigational New Drug (IND) application. By defining the CQAs of your molecule early, you establish a clear analytical framework for manufacturing process control and release testing. This proactive approach minimizes regulatory risk and supports an accelerated development timeline.

Our work within our >100,000 sq ft facility is designed to support a predictable 18-24 month IND timeline. This operational efficiency, combined with deep scientific expertise, has enabled our teams to maintain a 100% IND success rate since 2019. The Franklin Biolabs brand itself launched in 2024, building upon this proven legacy. We integrate these advanced proteomics services with comprehensive bioanalytical and toxicology programs, providing a cohesive data package for regulatory review.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities